此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

改善高能量骨科创伤后的疼痛管理和长期结果(疼痛研究) (PAIN)

2026年11月9日 更新者:Major Extremity Trauma Research Consortium

The purpose of this study is to definitively resolve questions regarding the use of multimodal pharmacologic pain management for orthopedic trauma patients in the context of a multicenter, randomized clinical trial.

Also, as a significant proportion of this population develops chronic post traumatic osteoarthritis (PTOA), a sub-objective of this study is to examine the etiology and incidence of chronic pain and PTOA in this population.

研究概览

详细说明

In this study, will test whether adjunctive analgesic therapy during the pre and peri-operative period, in addition to standard of care pain management, can improve overall pain control and pain related outcomes without increasing analgesic related side effects.

Patients will be randomized into three treatment groups. The intervention will begin within 48 hours of admission and continue for up to the time of definitive fixation.

Group 1: standard pain management, plus intravenous and oral placebo for up to 48 hours following definitive fixation.

Group 2: standard pain management, plus intravenous NSAIDs (ketorolac) and oral placebo for up to 48 hours following definitive fixation.

Group 3: standard pain management, plus intravenous placebo and oral pregabalin for up to 48 hours following definitive fixation.

Specific Aim 1: Evaluate the effect of standard pain management (Group 1) vs. standard pain management plus peri-operative NSAIDs (Group 2 - meloxicam + ketorolac) in the treatment of severe limb fractures.

Hypothesis 1a: When compared to patients who received standard of care pain management, patients treated with NSAIDs will: (1) have reduced post operative opioid utilization; (2) report reduced levels of persistent pain; and (3) have noninferior rates of surgery for nonunion.

Hypothesis 1b: When compared to patients who received standard of care pain management, patients treated with NSAIDs will benefit from (1) improved post operative pain control; (2) improved pre operative pain control; (3) reduced lengths of stay; (4) reduced pain interference; (5) improved functional outcomes; (6) lower levels of depression and post-traumatic stress disorder (PTSD); (7) improved overall health status; and (8) have noninferior rates of analgesic treatment related side effects.

Specific Aim 2: Evaluate the effect of standard pain management (Group 1) vs. standard pain management plus pre and peri-operative pregabalin (Group 3) in the treatment of severe limb fractures.

Hypothesis2a : When compared to patients who received standard of care pain management, patients treated with pregabalin will: (1) have reduced post operative opioid utilization; (2) report reduced levels of persistent pain; and (3) have noninferior rates of surgery for nonunion.

Hypothesis 2b: When compared to patients who received standard of care pain management, patients treated with pregabalin will benefit from (1) improved post operative pain control; (2) improved pre operative pain control; (3) reduced lengths of stay; (4) reduced pain interference; (5) improved functional outcomes; (6) lower levels of depression and post-traumatic stress disorder (PTSD); (7) improved overall health status; and (8) have noninferior rates of analgesic treatment related side effects.

Specific Aim 3: Estimate the incremental cost effectiveness of each adjunctive analgesic therapy relative to standard of care analgesic therapy in the treatment of severe limb fractures. Costs will be estimated from both the health care provider perspective and the societal perspective. The time horizon for cost-effectiveness analysis will be based on the actual period of observation. Incremental cost-effectiveness ratios will be calculated for: (a) study group 2 (NSAIDS - meloxicam + ketorolac) relative to standard of care; and (b) study group 3 (pregabalin) relative to standard of care. For purpose of cost-effectiveness analysis, the effect will be measured as unit change in specific outcome metrics at up to 15 months (or longer period as available) compared to baseline. The following cost-effectiveness metrics, all relative to standard of care, will be reported:

  1. incremental cost per unit change in the Brief Pain Inventory
  2. incremental cost per unit change in the Short Muscular Function Assessment (SFMA)
  3. incremental cost per unit change in health state preference ("utility") as derived from the VR-12.

PTOA Pilot Study: Additional funding was received from NIH to conduct a pilot, observational study of post-traumatic osteoarthritis (PTOA), leveraging current resources of the Pain study. PTOA is an important outcome in the population to be enrolled in the Pain study. The aims of the PTOA Study are to: (1) measure the incidence of PTOA and chronic pain for up to 24 months following fracture reduction surgery and (2) quantify the extent to which fracture severity and post-reduction contact stress are related to the development of PTOA. Accomplishment of these aims will require (1) for all patients with ankle fractures in the Pain study: complete a PTOA survey at 12 months and at any subsequent visits that are conducted as part of standard of care and provide access to all standard of care imaging studies completed during the study period and (2) for a subset of 60 pilon fracture patients enrolled in the Pain study for whom post-operative CT scans are not standard of care, obtain additional consent for completion of a study-funded post-operative CT scan and 24 month radiographic study

研究类型

介入性

注册 (实际的)

450

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Florida
      • Miami、Florida、美国
        • University of Miami Ryder Trauma Center
      • West Palm Beach、Florida、美国
        • St. Mary's Medical Center
    • Indiana
      • Indianappolis、Indiana、美国
        • Eskenazi Health
    • Iowa
      • Iowa City、Iowa、美国
        • University of Iowa Hospitals & Clinics
    • Louisiana
      • Shrevport、Louisiana、美国
        • Louisiana State University Health Sciences Center
    • Maryland
      • Baltimore、Maryland、美国
        • Johns Hopkins University
      • Baltimore、Maryland、美国
        • University of Maryland, R Adams Cowley Shock Trauma Center
    • Massachusetts
      • Boston、Massachusetts、美国
        • Boston Medical Center
    • Minnesota
      • Minneapolis、Minnesota、美国
        • Hennepin County Medical Center
    • North Carolina
      • Charlotte、North Carolina、美国
        • Carolinas Medical Center
    • Ohio
      • Cleveland、Ohio、美国
        • MetroHealth Medical Center
    • Pennsylvania
      • Hershey、Pennsylvania、美国
        • Penn State University M.S. Hershey Medical Center
      • Pittsburgh、Pennsylvania、美国
        • University of Pittsburgh
    • Tennessee
      • Nashville、Tennessee、美国
        • Vanderbilt University Medical Center
    • Texas
      • Dallas、Texas、美国
        • University of Texas Southwestern Medical Center
      • Houston、Texas、美国
        • UT Health: The University of Texas Health Science Center at Houston Medical School
    • Virginia
      • Portsmouth、Virginia、美国
        • Naval Medical Center Portsmouth

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients with one of the following types of injuries:

    1. Unilateral, Grade I &II open or closed pilon (distal tibial plafond), calcaneus, talus fractures and Lisfranc dislocations requiring operative treatment with fixation; or
    2. Unilateral, open (type I, II, or IIIA) ankle fractures with associated dislocation on presentation (OTA 44B3 or 44C) requiring operative treatment with fixation; or
    3. Unilateral, open or closed distal and proximal humerus (OTA 11A-C and OTA 13 A-C); or
    4. Open femoral shaft fracture (OTA 32 A-C; Gustilo Type I-IIIC) or open or closed supracondylar femur fractures (OTA 33 A-C); or
    5. Open or closed tibial plateau or shaft fractures (OTA 42 A-C or 43 A-C)
    6. Any combination of the above injuries which are surgically treated as a whole
  2. Patients who present to the admitting hospital acutely or clinic following an initial assessment in the Emergency Department, for care up to 10 days following initial injury.

  3. Patients 18-80 years old inclusive.

  4. Patients who are English or Spanish competent.

  5. Treating physicians agree that none of the study drugs are indicated for standard of care treatment for this patient.

  6. Patients able to be followed at the METRC facility for at least 12 months following injury.

Exclusion Criteria:

  1. Patients unable to provide informed consent.
  2. Patients with chronic pain being presently treated with opioid or gabapentinoid prescription or any other alternative therapy.
  3. Patients who are current IVDA
  4. Patients with bilateral or ipsilateral injuries requiring surgery
  5. Patients with other orthopedic or non-orthopedic injuries requiring operative intervention
  6. Patients with severe osteopenia.
  7. Patients who are skeletally immature (defined as less than 18 years of age or no radiographic evidence of epiphyseal closure).
  8. Patients who are expected to have a post-surgical stay less than 24 hours.
  9. Patients with a history of allergy to any drugs in the study.
  10. Patients unable to swallow oral medications or without adequately functioning GI tract.
  11. Patients with a history of gastrointestinal bleeds or gastric perforation.
  12. Patients with a history of stroke or heart attack.
  13. Patients currently receiving an aspirin or NSAID regimen (exception: low dose (81 mg) aspirin. See section 6.5) Patients with any bleeding disorders.
  14. Patients with severe renal failure. Patients with moderate renal failure may participate in the study at a modified dose. See Section 9.6.
  15. Patients undergoing daily treatment with systemic glucocorticoids before surgery.
  16. Patients using angiotensin-converting enzyme (ACE) inhibitors, who may be at increased risk of developing angioedema with pregabalin.
  17. Patients likely to have severe problems maintaining follow-up, including patients diagnosed with a severe psychiatric conditions, patients who live too far outside the hospital's catchment area, patients who are incarcerated and patients who have unstable housing situations.
  18. Patients who experienced a loss of consciousness consistent with a clinical diagnosis of a closed head injury, or concern of a cerebrovascular bleed secondary to traumatic brain injury.
  19. Patients with a GCS <15
  20. Patient speaks neither English nor Spanish.
  21. Patients who are pregnant or lactating at time of screening

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Standard pain management + perioperative intravenous placebo & oral placebo.

Control group will receive an oral dose of placebo up to two hours prior to surgery and twice daily for up to 48 hours following any surgery, in addition to an intravenous dose of placebo up to two hours prior to surgery and every 6 hours for up to 48 hours following surgery. All study medications will be in addition to standard of care pain medication.

*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall.

有源比较器:NSAID

Standard pain management + perioperative intravenous ketorolac & oral placebo.

The NSAID group will receive 30 mg of intravenous (IV) ketorolac (Ketorolac 30 mg/ml dose vial, NDC 00409-3795-01; manufacturer: Hospira) administered up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an oral dose of placebo up to two hours prior to the procedure and every 12 hours for up to 48 hours following the procedure.

*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall.

其他名称:
  • 美洛昔康/Mobic(NDC 68382-000-01;制造商:Zydus;封装在 AA 尺寸中
  • 空胶囊壳,由 Fisher Clinical Services(布里斯托尔)用 Avicel 回填
  • 有限责任公司)
  • Ketorolac/Toradol(NDC 00409-3795-01;制造商:Hospira)
有源比较器:Gabapentinoid

Standard pain management + perioperative intravenous placebo & oral pregabalin.

The Pregabalin group will receive an oral bolus dose of 300 mg of pregabalin up to two hours prior to the procedure and a 75 mg dose every 12 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an IV dose of placebo up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure.

*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall.

其他名称:
  • Pregablin/Lyrica(NDC 00071-1014-68;制造商:Pfizer;封装尺寸
  • AA 空胶囊壳,用 Fisher Clinical Services 的 Avicel 回填
  • (布里斯托尔)有限责任公司; Lyrica, NDC 00071-1018-68;制造商:辉瑞;封装的
  • AA 号空胶囊壳,用 Fisher Clinical 的 Avicel 回填
  • 服务(布里斯托尔)有限责任公司)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Opioid Utilization
大体时间:48 hours after last definitive fixation

Morphine equivalent opioid utilization during initial hospitalization through 48 hours following definitive fixation.

48 hours after last definitive fixation
Persistent Pain
大体时间:90 days

Patient reported persistent pain states measured using the Brief Pain Inventory (BPI) .

90 days
Surgery for non-union
大体时间:1 year

Defined as non-prophylactic surgery for nonunion performed between six months and a year following initial hospital discharge.

1 year

次要结果测量

结果测量
措施说明
大体时间
Adverse Effects and Complications
大体时间:2-3 weeks

Will include nonunion, wound closure complications, bleeding complications (particularly perioperative bleeding due to loss of platelet function and gastrointestinal bleeding), as well as pain treatment related adverse effects. These include nausea, vomiting, constipation, sedation, pruritis, respiratory depression, somnolence, dizziness, headaches, coordination problems, peripheral edema, blurred vision, gastrointestinal symptoms and irritation, renal impairment, platelet inhibition, angioedema, and post operative delirium. Adverse effects and complications will be assessed by both patient report of symptoms during the period between enrollment and 48 hours post definitive fixation, and by clinical survey of symptoms during index hospitalization and at discharge from additional surgical admissions up to definitive fixation.

2-3 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Lawrence Marsh, MD、University of Iowa Hospitals & Clinics
  • 研究主任:Katherine Frey, RN, MPH, MS、Johns Hopkins Bloomberg School of Public Health
  • 首席研究员:Renan Castillo, PhD、Johns Hopkins Bloomberg School of Public Health

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2013年7月1日

初级完成 (实际的)

2018年12月31日

研究完成 (实际的)

2018年12月31日

研究注册日期

首次提交

2013年2月7日

首先提交符合 QC 标准的

2013年2月11日

首次发布 (估计的)

2013年2月12日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅